Arcticzymes Technology (AZT) la frem en meget sterk rapport før helgen. Selskapet utvikler enzymer som driver alle kjemiske livsprosesser.

Enzymene ArcticZymes Technologies utvikler brukes som komponenter i diagnostiske tester, molekylær forskning og biofarmasøytisk produksjon. Når innovasjon fra Tromsø brukes i laboratorier over hele verden setter det byen på kartet i internasjonal skala.

https://www.nordlys.no/vis/annonse/arcticzymes-ansetter/?utm_source=www.nordlys.no&fbclid=IwAR3sBlNRCnLJwU8JIGL1Vx-KWFFRsh-7yYLmYDLZufAsr_eKo2E3vCbA4yY

Selskapet rapporterer nå om sterke utsikter fremover og markedet sender aksjen kraftig oppover. AZT-aksjen ble handlet til over 100 kroner for få år siden. Veien til det nivået igjen kan ha startet.

ArcticZymes Technologies announces Q4 2024 Financial results Tromsø, Norway, February 13th, 2025 - ArcticZymes Technologies (OSE: AZT)
reported total revenues of NOK 26.4 million and an EBITDA of NOK 2.7 million for the fourth quarter of 2024.

"In Q4, we made significant strides in strengthening our commercial capabilities and laying the foundation for long-term growth. While revenues reflect a transition period, our EBITDA improvement and quarter on quarter revenue growth highlights progress. With a strengthened commercial team, new product launches, and strategic partnerships ahead, we are well-positioned to support the evolving needs of our customers. 2025 will be a year of execution, focusing on customer-centric innovation and commercial transformation to drive sustainable growth." Commented Michael Akoh, CEO of ArcticZymes Technologies.

Strategic Focus on Partnerships and Direct Sales Recognizing the importance of collaboration and customer engagement, ArcticZymes has emphasized both strategic partnerships and direct sales as critical components of its long-term strategy:

· Partnerships: Collaborating with leading organizations remains a cornerstone of ArcticZymes' growth strategy. SAN OEM agreement discussions continued
positively in the quarter. Additionally, the integration of M-SANQ HQ into a leading viral vector CDMO's manufacturing protocols, starting in Q2 2025,
highlights the importance of partnerships in broadening market access.
· Direct Sales: Direct engagement with customers continues to be a key priority. This approach enables ArcticZymes to gain valuable feedback, adapt to
client needs, and innovate more effectively. By maintaining close relationships with customers, the company ensures its solutions remain highly relevant and
impactful. The commercial team has been restructured and strengthened with the addition of new experienced Business Developers and a Marketing Director. This
revamped team is instrumental in creating a customer-centric organization, ensuring that ArcticZymes is well-positioned to address client challenges and deliver tailored solutions.

Operational Improvements ArcticZymes has made significant investments in its operational infrastructure and hereby also scalling abilities.

· The successful implementation of a new Enterprise Resource Planning (ERP) system, Jeeves, enhances scalability and operational efficiency. The system went
live December 2[th], 2024 and will support both compliance as well as scalabity throughout the value chain.

Outlook for 2025 The combination of strategic partnerships, customer centric transformation, and a robust innovation pipeline will enable the company to meet market demands, drive growth, and deliver value to clients and shareholders.

https://newsweb.oslobors.no/message/638489